COLUCCI, Mario
 Distribuzione geografica
Continente #
NA - Nord America 8.037
EU - Europa 1.786
AS - Asia 590
SA - Sud America 5
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 3
Totale 10.425
Nazione #
US - Stati Uniti d'America 8.032
CN - Cina 536
SE - Svezia 449
DE - Germania 404
UA - Ucraina 250
IT - Italia 234
FI - Finlandia 156
FR - Francia 103
GB - Regno Unito 88
IE - Irlanda 40
IN - India 22
BE - Belgio 21
RU - Federazione Russa 18
SG - Singapore 9
CZ - Repubblica Ceca 6
CA - Canada 5
NL - Olanda 5
IR - Iran 4
KR - Corea 4
VN - Vietnam 4
AU - Australia 3
EU - Europa 3
AR - Argentina 2
BR - Brasile 2
IL - Israele 2
PL - Polonia 2
SK - Slovacchia (Repubblica Slovacca) 2
AE - Emirati Arabi Uniti 1
AT - Austria 1
AZ - Azerbaigian 1
BG - Bulgaria 1
ES - Italia 1
GR - Grecia 1
HK - Hong Kong 1
HU - Ungheria 1
ID - Indonesia 1
IS - Islanda 1
KW - Kuwait 1
LU - Lussemburgo 1
MN - Mongolia 1
NZ - Nuova Zelanda 1
PE - Perù 1
PK - Pakistan 1
RO - Romania 1
TR - Turchia 1
UZ - Uzbekistan 1
Totale 10.425
Città #
Fairfield 1.157
Woodbridge 1.029
Houston 689
Chandler 671
Jacksonville 606
Ashburn 549
Seattle 501
Cambridge 414
Ann Arbor 397
Wilmington 388
Nyköping 384
Roxbury 162
Lawrence 160
Nanjing 158
Des Moines 96
Beijing 89
Bari 87
Boardman 69
New York 65
Princeton 61
San Diego 61
Inglewood 53
Strasbourg 49
Hebei 42
Brooklyn 41
Nanchang 41
Dublin 39
Shenyang 39
Grafing 37
Tianjin 25
Brussels 21
Dearborn 20
Jiaxing 20
Changsha 19
London 17
Paris 17
Pune 15
Los Angeles 12
Frankfurt am Main 11
Auburn Hills 10
Guangzhou 10
Redwood City 10
Kunming 9
San Mateo 9
Jinan 8
Rome 8
Augusta 7
Foggia 6
Zhengzhou 6
Brno 5
Mola Di Bari 5
Norwalk 5
Singapore 5
Dong Ket 4
Helsinki 4
Milan 4
Munich 4
Napoli 4
Ningbo 4
Toronto 4
Wuhan 4
Ardabil 3
Bethlehem 3
Chicago 3
Detroit 3
Heze 3
Hounslow 3
Indiana 3
Leawood 3
Lecce 3
Monmouth Junction 3
Quanzhou 3
San Francisco 3
San Pietro in Cariano 3
Capraia e Limite 2
Chengdu 2
Chongqing 2
Cutrofiano 2
Guagnano 2
Hangzhou 2
Kilburn 2
La Plata 2
Melbourne 2
Monopoli 2
Mumbai 2
Noci 2
Rogeno 2
Salerno 2
Salsomaggiore Terme 2
Shanghai 2
São Paulo 2
Taranto 2
Tel Aviv 2
Trento 2
Washington 2
Altamura 1
Amsterdam 1
Andria 1
Artogne 1
Barletta 1
Totale 8.532
Nome #
Platelet drop and fibrinolytic shutdown in patients with sepsis 122
Histones differentially modulate the anticoagulant and profibrinolytic activities of heparin, heparin derivatives and dabigatran. 119
Factor IX-Padua enhances the fibrinolytic resistance of plasma clots 115
Coagulation activation is associated with nicotinamide adenine dinucleotide phosphate oxidase-dependent reactive oxygen species generation in hemodialysis patients. 113
Dabigatran but not rivaroxaban or apixaban treatment decreases fibrinolytic resistance in patients with atrial fibrillation 108
Influence of cell-associated tissue factor concentration on the anticoagulant activity of dabigatran. A possible explanation for the reduced incidence of intracranial bleeding 106
Cultured human endothelial cells generate tissue factor in response to endotoxin 105
Tissue factor in health and disease 104
Coagulopathy of Acute Sepsis 104
Hypercoagulability in patients with Cushing disease detected by thrombin generation assay is associated with increased levels of neutrophil extracellular trap-related factors 104
Hyperprothrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediated mechanism 103
Co-administration of low molecular weight heparin enhances the profibrinolytic effect of warfarin through different mechanisms. 102
A modified prothrombin time to measure the anticoagulant activity of dabigatran 102
Grape intake reduces thrombin generation and enhances plasma fibrinolysis. Potential role of circulating procoagulant microparticles 100
Fisiologia dell'Emostasi 99
In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis. Study in healthy subjects and correlation with blood fibrinolytic parameters 98
Reduced fibrinolytic resistance in patients with factor XI deficiency. Evidence of a thrombin-independent impairment of the thrombin-activatable fibrinolysis inhibitor pathway 98
Effect of warfarin treatment on thrombin activatable fibrinolysis inhibitor (TAFI) activation and TAFI-mediated inhibition of fibrinolysis 97
Profibrinolytic activity of the direct thrombin inhibitor melagatran and unfractionated heparin in platelet-poor and platelet-rich clots 97
Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein C reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation 96
A novel nitric oxide-releasing statin derivative exerts an antiplatelet/antithrombotic activity and inhibits tissue factor expression 96
Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation 95
Role of leucocyte procoagulant activity in endotoxin-induced DIC: evidence from comparative studies in rats and rabbits. 95
Effect of ochratoxin A on prothrombotic and proinflammatory activities of stimulated blood mononuclear cells 95
Platelets and fibrinolysis 93
Sepsis, thrombosis and organ dysfunction 92
Changes in coagulation-fibrinolysis balance in blood mononuclear cells and in gastric mucosa from patients with Helicobacter pylori infection 91
Reduced generation of procoagulant activity by endotoxin-stimulated mononuclear cells from patients with chronic myeloid leukaemia. 89
Antithrombotic activity of 12 table grape varieties. Relationship with polyphenolic profile 89
TAFI deficiency in liver cirrhosis: relation with plasma fibrinolysis and survival 88
FAILURE OF WARFARIN TO AFFECT THE TISSUE FACTOR ACTIVITY AND THE METASTATIC POTENTIAL OF MURINE FIBRO-SARCOMA CELLS. 87
Non neutralizing antibodies to tissue type plasminogen activator in the serum of acute myocardial infarction patients treated with the recombinant protein. 87
CHANGES IN THE COAGULATION-FIBRINOLYSIS BALANCE OF ENDOTHELIAL-CELLS AND MONONUCLEAR PHAGOCYTES - ROLE IN DISSEMINATED INTRAVASCULAR COAGULATION ASSOCIATED WITH INFECTIOUS-DISEASES 87
Angiotensin IV stimulates plasminogen activator inhibitor-1 expression in proximal tubular epithelial cells 86
Complement-dependent and complement-independent interactions of bacterial lipopolysaccharides and mucopeptides with rabbit and human platelets. 84
Thrombolysis enhancing activity of a low molecular weight dermatan sulfate (Desmin 370) in experimental pulmonary embolism in rats. 84
Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor 84
In vitro inhibition of monocyte tissue factor and PAI-2 production by Ochratoxin A 83
Blood and tissue fibrinolytic profile in patients with colorectal cancer 83
Procoagulant activity of sarcoma sublines with different metastatic potential 82
Monocytes, but not endothelial cells, downregulate the anticoagulant activity of activated protein C 82
Hyperprothrombinemia-induced APC resistance: differential influence on fibrin formation and fibrinolysis 82
Stroke in two young siblings with congenital dysfibrinogenemia. 81
Impaired fibrinolysis in obstructive jaundice--evidence from clinical and experimental studies 81
null 80
Treatment with cyclosporin A does not affect macrophage procoagulant activity and plasminogen activator inhibitor in mice 80
Cancer cell procoagulant: a novel vitamin K-dependent activity. 80
Unbalanced coagulation-fibrinolysis potential during L-Asparaginase therapy in children with acute lymphoblastic leukaemia 78
ENHANCED ENDOTHELIAL TISSUE FACTOR BUT NORMAL THROMBOMODULIN IN ENDOTOXIN-TREATED RABBITS. 78
Low D-dimer levels in sepsis: Good or bad? 78
Mild hyperhomocysteinemia is associated with increased TAFI levels and reduced plasma fibrinolytic potential 77
Warfarin inhibits both procoagulant activity and metastatic capacity of Lewis lung carcinoma cells. Role of vitamin K deficiency. 76
Reduction of the plasma levels of tissue plasminogen activator after infusion of a lipid emulsion in humans 76
A hitherto undescribed defect of platelet coagulant activity in polycythaemia vera and essential thrombocythaemia. 76
Cancer cell procoagulant activity: evaluation by an amidolytic assay. 76
Increased mononuclear cell tissue factor and type-2 plasminogen activator inhibitor and reduced plasma fibrinolytic capacity in children with lymphoma 75
Helicobacter pylori neutrophil-activating protein stimulates tissue factor and plasminogen activator inhibitor-2 production by human blood mononuclear cells 75
Early increase of a new platelet coagulant activity in rats fed a thrombogenic diet. 75
Ochratoxin A inhibits the production of tissue factor and plasminogen activator inhibitor-2 by human blood mononuclear cells: Another potential mechanism of immune-suppression 74
FVIII/VWF complex displays a greater pro-hemostatic activity than FVIII preparations devoid of VWF. Study in plasma and cell-based models 74
Does inhibiting Sur1 complement rtPA in cerebral ischemia? 73
Increased macrophage procoagulant activity but normal endothelial thrombomodulin in rabbits fed an atherogenic diet 73
Effect of Ochratoxin A on prothrombotic and proinflammatory activities of stimulated blood mononuclear cells 73
Cultured human mesangial cells produce both type 1 and type 2 plasminogen activator inhibitors 73
Gene expression signature induced by grape intake in healthy subjects reveals wide-spread beneficial effects on peripheral blood mononuclear cells 73
EXPERIMENTAL ENDOTOXEMIA AS A MODEL OF IMPAIRED FIBRINOLYSIS 72
REDUCED FIBRINOLYTIC-ACTIVITY IN GLOMERULI ISOLATED FROM RABBITS INFUSED WITH TUMOR-NECROSIS-FACTOR. 72
Skin extracts from 2 italian table grapes (italia and palieri) inhibit tissue factor expression by human blood mononuclear cells 72
Rebuttal to: Effect of heparin on TAFI-dependent inhibition of fibrinolysis 72
URINARY PROCOAGULANT AND FIBRINOLYTIC-ACTIVITY IN HUMAN GLOMERULONEPHRITIS - RELATIONSHIP WITH RENAL-FUNCTION 71
Procoagulant properties of bare and highly-PEGylated vinyl-modified silica nanoparticles 71
The paradoxical antifibrinolytic effect of dabigatran and argatroban in the presence of soluble thrombomodulin is unrelated to protein C-dependent increase of thrombin generation. 70
Fibrin down-regulates LPS- and PMA- induced tissue factor expression by blood mononuclear cells 69
Sepsis-associated disseminated intravascular coagulation and thromboembolic disease. 67
PLASMINOGEN ACTIVATOR INHIBITOR IN THE BLOOD OF PATIENTS WITH CORONARY-ARTERY DISEASE. 66
Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis 65
Thrombin Activatable Fibrinolysis Inhibitor: at the nexus of fibrinolysis and inflammation 65
Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA 65
Retinoic acid stimulates plasminogen activator inhibitor 2 production by blood mononuclear cells and inhibits urokinase-induced extracellular proteolysis 64
Increased production of mononuclear cell procoagulant activity in Hodgkin's disease. 64
The role of thrombin activatable fibrinolysis inhibitor and factor XI in platelet-mediated fibrinolysis resistance: a thromboelastographic study in whole blood 64
Cellular coagulation-fibrinolysis balance and atherosclerosis 63
A ROLE FOR PLATELETS AND THROMBIN IN THE JUVENILE STROKE OF 2 SIBLINGS WITH DEFECTIVE THROMBIN-ADSORBING CAPACITY OF FIBRIN(OGEN) 63
EFFECT OF HEPARIN AND OR ANTITHROMBIN-III ON THE GENERATION OF ENDOTOXIN-INDUCED PLASMINOGEN-ACTIVATOR INHIBITOR. 63
Expression of tissue factor and vascular endothelial growth factor in colorectal carcinoma 63
Prevention and therapy of experimental venous thrombosis in rabbits by desmin 370 62
HEMOSTATIC VARIABLES IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA - EFFECT OF REGULAR PLASMA-CHOLESTEROL REMOVAL BY LOW-DENSITY-LIPOPROTEIN APHERESIS 62
Monoclonal antibodies targeting the antifibrinolytic activity of activated TAFI but not the anti-inflammatory activity on osteopontin and C5a 61
Evidence that cells from experimental tumours can activate coagulation factor X. British journal of cancer. 61
Platelets abolish the profibrinolytic effect of activated protein C 61
Generation of procoagulant activity by mononuclear phagocytes: a possible mechanism contributing to blood clotting activation within malignant tissues. 61
TISSUE FACTOR-EXPRESSING MONOCYTES INHIBIT FIBRINOLYSIS THROUGH A TAFI-MEDIATED MECHANISM, AND MAKE CLOTS RESISTANT TO HEPARINS 61
D-dimer corrected for thrombin and plasmin generation is a strong predictor of mortality in patients with sepsis 61
PROPERTIES OF CHIMERIC (TISSUE-TYPE UROKINASE-TYPE) PLASMINOGEN ACTIVATORS OBTAINED BY FUSION AT THE PLASMIN CLEAVAGE SITE 60
How a β-D-Glucoside Side Chain Enhances Binding Affinity to Thrombin of Inhibitors Bearing 2-Chlorothiophene as P1 Moiety: Crystallography, Fragment Deconstruction Study and Evaluation of Antithrombotic Properties 59
Cellular and plasmatic anomalies of the coagulation system and fibrinolysis in children with lymphomas and influence of cytostatic treatment 58
Influence of the fast-acting inhibitor of plasminogen activator on in vivo thrombolysis induced by tissue-type plasminogen activator in rabbits. Interference of tissue-derived components 58
Platelet aggregation and stimulation of leucocyte procoagulant activity by rickettsial lipopolysaccharides in rabbits and in man. 57
Identification of plasminogen activator releasing activity in the neurohypophysis. 57
Procoagulant activity of mononuclear phagocytes from different anatomical sites in patients with gynecological malignancies 57
Totale 8.018
Categoria #
all - tutte 40.406
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.406


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.805 498 161 64 273 315 177 292 261 364 113 216 71
2020/20211.468 142 104 124 70 169 95 113 146 169 203 81 52
2021/20221.175 57 200 11 40 60 51 63 53 80 63 200 297
2022/20231.810 265 194 135 163 213 234 24 172 327 13 36 34
2023/2024472 59 102 17 36 31 105 15 21 5 11 18 52
2024/202538 38 0 0 0 0 0 0 0 0 0 0 0
Totale 10.524